Tesamorelin and Retatrutide – fat reduction and metabolic health

Both tesamorelin and retatrutide are being investigated for fat reduction and improved metabolic health, however, they operate via completely different biological mechanisms. Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue that stimulates the natural production of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Retatrutide, on the other hand, is a triple incretin receptor agonist acting on GLP-1, GIP, and glucagon receptors. For this reason, both compounds affect appetite, fat metabolism, body composition, glucose control, and energy balance in entirely different ways. The comparison of Tesamorelin and Retatrutide is gaining increasing popularity among individuals interested in modern approaches to fat reduction, improvement of metabolic parameters, and optimisation of body composition.

Mechanism of action – GH pathway vs triple incretin activation

Tesamorelin works primarily via the GH–IGF-1 axis. By stimulating the pituitary gland to increase the secretion of natural growth hormone, it enhances lipolysis, which is the breakdown of stored body fat. Its effects are particularly associated with reducing visceral fat, improving body composition, and preserving lean muscle mass. Unlike many anti-obesity medications, tesamorelin does not primarily work by suppressing appetite. Its effects arise mainly from the hormonal regulation of fat metabolism and the activation of the GH pathway.

Retatrutide works in a completely different way. It combines three metabolic mechanisms in one therapy. GLP-1 receptor activation helps to reduce appetite and improve glycaemic control. GIP receptor activation supports metabolic regulation and nutrient utilisation. In turn, glucagon receptor activation increases energy expenditure and fat oxidation. The combination of these mechanisms leads to a reduction in calorie intake, improved insulin sensitivity, increased fat burning, and a very significant reduction in body weight. Systematic reviews, including the study by Xiao et al., have shown that retatrutide significantly improved HbA1c, fasting glucose levels, body weight, BMI, blood pressure, and lipid markers in individuals with obesity and type 2 diabetes.

Effects of fat tissue reduction

Tesamorelin is usually associated more with selective visceral fat reduction rather than significant overall weight loss. As it stimulates endogenous GH secretion, its effects primarily focus on reducing deep abdominal fat, improving body composition, and preserving muscle mass. This is one of the reasons why tesamorelin has been extensively studied in HIV-associated lipodystrophy and metabolic disorders.

Retatrutide results in a significantly greater reduction in total body weight. Clinical trials summarised in systematic reviews have shown dose-dependent weight loss of up to approximately 24% at higher doses. Singh et al. reported weight loss of up to 26 kilograms in obesity studies, with many participants achieving total weight loss of over 15–20%.

Phase II trials demonstrated a reduction in body weight of approximately 8.7–24.21%, along with significant improvements in waist circumference, BMI, and markers of visceral fat and central obesity. Adipose tissue studies also showed that retatrutide increases fatty acid oxidation, mitochondrial activity, lipolysis and metabolic flexibility, whilst reducing lipogenesis and adipose tissue fibrosis.

Impact on metabolic health

Tesamorelin can improve metabolic health primarily through visceral fat reduction, improved lipid metabolism, possible reduction in liver fat, and increased GH-dependent lipolysis. However, GH-related therapies can sometimes transiently worsen insulin sensitivity in some individuals, as growth hormone antagonises insulin's effects on glucose metabolism.

Retatrutide appears to offer significantly broader metabolic benefits affecting multiple systems in the body. Meta-analyses have shown a significant reduction in HbA1c, fasting glucose, blood pressure and markers of insulin resistance, as well as an improvement in the lipid profile. Multi-omic adipose tissue studies have also shown that retatrutide increases adiponectin levels, lowers leptin, reduces inflammatory signalling, inhibits adipose tissue fibrosis, improves glucose tolerance and improves liver markers such as ALT and AST.

Crucially, researchers observed that retatrutide not only reduces the amount of fat tissue. It also appears to transform dysfunctional fat tissue into a more metabolically active and oxidative form, thereby improving the metabolic quality of the tissue itself.

GH Peptides vs. GLP-1 Based Therapies

The comparison of tesamorelin and retatrutide highlights two very different approaches to metabolic optimisation.

Tesamorelin and other GH-related peptides are more commonly associated with visceral fat reduction, increased GH and IGF-1 activity, enhanced lipolysis, possible muscle mass preservation, and a more moderate weight loss. These therapies are less associated with appetite suppression and more with improved body composition and hormonal regulation.

Retatrutide and other GLP-1-based therapies, on the other hand, are strongly associated with appetite suppression, significant reduction in total body weight, improved glycaemic control, increased energy expenditure, broad cardiometabolic benefits, and anti-inflammatory effects within adipose tissue.

Activation of glucagon receptors by retatrutide may further increase fat burning and energy expenditure more than classical GLP-1 agonists. Analysis of adipose tissue revealed activation of genes associated with fatty acid degradation and oxidative metabolism, which supports this mechanism of action.

Safety and tolerance

The adverse effects of tesamorelin are usually related to increased GH and IGF-1 activity. The most commonly reported effects include:

• Water retention
• swellings
• joint pain
• changes in insulin sensitivity
• Injection site reactions

The side effects of retatrutide are mainly gastrointestinal. The most frequently reported symptoms include:

• nausea
• Vomiting
• Constipation
• Diarrhoea

Systematic reviews have shown that gastrointestinal symptoms were the most frequent adverse events, particularly at higher doses.

Summary

Tesamorelin and retatrutide represent two entirely different approaches to fat reduction and metabolic health improvement. Tesamorelin acts by stimulating the natural GH axis and appears particularly useful in reducing visceral fat, improving body composition, and supporting growth hormone-dependent metabolism. Retatrutide, as a triple agonist of GLP-1/GIP/glucagon receptors, appears to provide significantly greater overall body weight reduction and broad improvement in glucose regulation, lipid metabolism, adipose tissue inflammation, and metabolic functions.

Current evidence suggests that retatrutide may offer stronger and broader metabolic effects for the treatment of obesity and type 2 diabetes, while tesamorelin may remain of particular interest in situations where the primary goal is visceral fat reduction and support of the growth hormone axis.

From the perspective of the research peptides market, compounds such as tesamorelin are also available from suppliers such as Semax Polska exclusively for laboratory and scientific research.

Disclaimer

This content is for educational and informational purposes only and does not constitute medical, diagnostic or therapeutic advice. Tesamorelin is a medicine approved for specific medical indications, whilst retatrutide remains a compound currently undergoing clinical trials in many parts of the world. Therapies affecting growth hormone, incretin and metabolic pathways may carry risks and should only be used under the supervision of a qualified specialist with appropriate laboratory monitoring and individual medical assessment. Research-use-only peptides offered by suppliers such as Semax Polska are intended solely for laboratory and scientific research.